Cargando…

Therapy-Related Myeloid Malignancies in Myeloma

Therapy related myeloid malignancies are an increasingly recognized treatment complication in patients undergoing therapy for multiple myeloma. The main predisposing factors are the alkylating agents, topoisomerase II inhibitors and radiotherapy, but recently questions have been raised regarding the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papanikolaou, X., Barlogie, B., Usmani, S.Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2011
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219649/ https://www.ncbi.nlm.nih.gov/pubmed/22110897 http://dx.doi.org/10.4084/MJHID.2011.047

Ejemplares similares

Second Primary Malignancies and Myeloma Therapy: Fad or Fact?
por: Usmani, Saad Z.
Publicado: (2012)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
por: Atrash, S, et al.
Publicado: (2015)

Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia
por: Atrash, Shebli, et al.
Publicado: (2017)

Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma
por: Hu, Bo, et al.
Publicado: (2013)

CD38-Directed Therapies for Management of Multiple Myeloma
por: Hashmi, Hamza, et al.
Publicado: (2021)

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma
por: Heuck, C J, et al.
Publicado: (2014)

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma
por: Khan, R, et al.
Publicado: (2015)

Chromosome 1q21 abnormalities in multiple myeloma
por: Schmidt, Timothy M., et al.
Publicado: (2021)

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols
por: Singh, Zeba N, et al.
Publicado: (2015)

Telomerase-targeted therapies in myeloid malignancies
por: Waksal, Julian A., et al.
Publicado: (2023)

Thalidomide and its analogues in the treatment of Multiple Myeloma
por: Latif, Tahir, et al.
Publicado: (2012)

Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis
por: Papanikolaou, Xenofon, et al.
Publicado: (2014)

Barrett’s esophagitis related bronchoesophageal fistula - the diagnostic value of persistent air leak in the ventilated setting
por: Halaweh, O, et al.
Publicado: (2007)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

Differentiation therapy for myeloid malignancies: beyond cytotoxicity
por: Stubbins, Ryan J., et al.
Publicado: (2021)

A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy
por: Kleman, Ariel, et al.
Publicado: (2023)

TRANSMISSION OF MYELOID LEUKEMIA OF MICE : ITS RELATION TO MYELOMA
por: Furth, J.
Publicado: (1935)

Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis
por: Boquoi, A., et al.
Publicado: (2022)

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)
por: Papanikolaou, X, et al.
Publicado: (2016)

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
por: Shah, Nina, et al.
Publicado: (2020)

An Evaluation of Gene Set Analysis for Biomarker Discovery with Applications to Myeloma Research
por: Qu, Pingping, et al.
Publicado: (2017)

EVI1 dysregulation: impact on biology and therapy of myeloid malignancies
por: Birdwell, Christine, et al.
Publicado: (2021)

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
por: Bam, R, et al.
Publicado: (2014)

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
por: Razavi, P, et al.
Publicado: (2013)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2021)

The Role of PTEN in Myeloid Malignancies
por: Morotti, Alessandro, et al.
Publicado: (2015)

The molecular basis of myeloid malignancies
por: KITAMURA, Toshio, et al.
Publicado: (2014)

Role of the microenvironment in myeloid malignancies
por: Goulard, Marie, et al.
Publicado: (2017)

EZH2 in Myeloid Malignancies
por: Rinke, Jenny, et al.
Publicado: (2020)

Hedgehog Signaling in Myeloid Malignancies
por: Abraham, Ajay, et al.
Publicado: (2021)

Alternative Splicing in Myeloid Malignancies
por: Gurnari, Carmelo, et al.
Publicado: (2021)

Liquid biopsies in myeloid malignancies
por: Abdulmawjood, Bilal, et al.
Publicado: (2019)

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
por: Shoumariyeh, Khalid, et al.
Publicado: (2021)

The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies?
por: Heidel, Florian H., et al.
Publicado: (2021)

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
por: Bertoli, Sarah, et al.
Publicado: (2016)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020)

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma
por: Papanikolaou, X, et al.
Publicado: (2015)

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
por: Usmani, Saad Z., et al.
Publicado: (2018)

Myeloid malignancies: mutations, models and management
por: Murati, Anne, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6l4hmiukaik7j08usr40026ebq